Research paper

Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy

Congying Xie a,1, Pengfei Yang b,c,1, Xuebang Zhang a, Lei Xu b, Xiaoju Wang f, Xiadong Li b,d, Luhan Zhang b, Ruifei Xie f, Ling Yang f, Zhao Jing f, Hongfang Zhang f, Lingyu Ding f, Yu Kuang e, Tianye Niu b,**, Shixiu Wu g,**

a Cancer Centre, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, PR China
b Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China
c College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang, PR China
d Department of Radiation Therapy, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China
e Department of Medical Physics, University of Nevada, Las Vegas, Las Vegas, NV, USA
f Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China
g National Cancer Center/National Clinical Research Center For Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, PR China

A B S T R A C T

Background: Evaluating clinical outcome prior to concurrent chemoradiotherapy remains challenging for oesophageal squamous cell carcinoma (OSCC) as traditional prognostic markers are assessed at the completion of treatment. Herein, we investigated the potential of using sub-region radiomics as a novel tumour biomarker in predicting overall survival of OSCC patients treated by concurrent chemoradiotherapy.

Methods: Independent patient cohorts from two hospitals were included for training (n = 87) and validation (n = 46). Radiomics features were extracted from sub-regions clustered from patients’ tumour regions using K-means method. The LASSO regression for ‘Cox’ method was used for feature selection. The survival prediction model was constructed based on the sub-region radiomics features using the Cox proportional hazards model.

Findings: The overall survival prediction model combining with seven sub-regional radiomics features was constructed. The C-indexes of the proposed model were 0.729 (0.656–0.801, 95% CI) and 0.705 (0.628–0.782, 95%CI) in the training and validation cohorts, respectively. The 3-year survival receiver operating characteristic (ROC) curve showed an area under the ROC curve of 0.811 (0.670–0.952, 95%CI) in training and 0.805 (0.638–0.973, 95%CI) in validation. The correlation analysis showed a significant correlation between radiomics features and CNAs.

Interpretation: The proposed sub-regional radiomics model could predict the overall survival risk for patients with OSCC treated by definitive concurrent chemoradiotherapy.

1. Introduction

Previous studies revealed that biomarkers such as VEGF, cyclin D1, Ki-67, and squamous cell carcinoma antigen are prognostic for oesophageal squamous cell carcinoma (OSCC) [1]. These biomarkers are all derived from pathological analysis of tumour samples. Yet there remains a large cohort of OSCC patients who are physiologically unresectable or refused surgery. However, personalized treatment regimen and its long-term efficacy significantly rely on bio-physiological assessment of pre-treatment biomarkers. One alternative is through medical imaging...
assessment using computed tomography (CT), magnetic resonance (MR) and positron emission computed tomography (PET), which all play essential roles in cancer diagnosis and tumour heterogeneity analysis prior to radiotherapy. More specifically, PET/CT was used to predict survival in oesophageal cancer patients treated with chemoradiotherapy [2]. However, there has not been a literature consensus in terms of prognosis power in PET/CT. Atsumi et al. suggested the maximum standardized uptake value (SUVmax) as a strong prognostic marker for primary OSCC [3]. Lindner et al. found that SUVmax only correlates with survival of OSCC patient in case of primary surgery but not if patients received neoadjuvant therapy [4]. However, Myslivecek et al. concluded that the contribution of (18)F-FDG PET/CT cannot be considered as a potential marker for outcome of chemoradiotherapy [5]. The controversy over the use of SUVmax from PET/CT has hampered its utility in clinical practice. Meanwhile, efforts have been focusing on radiomics as a potential solution in providing surrogate information of the tumour microenvironment utilizing quantification methods such as texture analysis [6]. Beukinga et al. found that the combination of texture features extracted from PET and CT can improve the predictive power of tumour response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced OSCC, compared to SUVmax alone [7]. Despite strong clinical indication, the general clinical use of the PET/CT-based radiomics features in tumour response prediction is still limited, in part due to the high cost of PET/CT scans for patients especially in rural areas or developing countries. CT scans, on the other hand, are more accessible and recent studies have explored features extracted from CT alone. Hou et al. found that CT-based radiomics features can be used as imaging biomarkers to predict tumour response to chemoradiotherapy in OSCC patients [8]. Five CT-based radiomics features were found to discriminate responders from non-responders (AUCs from 0.686 to 0.727). Ganeshan et al. showed correlation between unenhanced CT textural features (entropy: p-value = .027, r = 0.512 and uniformity: p-value = .027, r = −0.521, Pearson’s correlation) and PET mean standardized uptake value (SUVmean) of non-small cell lung cancer (NSCLC) [9]. Ganeshan et al. applied the same methodology towards oesophageal carcinoma and found that entropy and uniformity are correlated with SUVmean (entropy: p-value < .001, r = 0.748 and uniformity: p-value < .001, r = −0.754, Pearson’s correlation) and SUVmax (entropy: p-value = .032, r = 0.469 and uniformity: p-value = .029, r = −0.476, Pearson’s correlation) in the corresponding 18F-FDG PET scans [10]. In other words, texture features from CT scans alone may be a prognostic indicator of survival prediction in OSCC. Thus far, OSCC tumour heterogeneity and its quantitative feature analysis has been carried out for the whole tumour volume, without the consideration of intra-tumoral variation in different sub-regions [11,12]. Yet sub-regional radiomics analysis has been conducted with proven prognostic power for NSCLC [13] and hepatocellular carcinoma [14]. To the best of our knowledge, no previous studies have applied sub-region based radiomics analysis for survival prediction of OSCC.

This study aimed to construct and validate a prognostic model for pre-treatment survival prediction of OSCC patients, based on sub-regional radiomics analysis of CT scans. To identify the clinical and molecular basis of quantitative imaging characteristics in this study, we assessed the association of the radiomics features with the clinical factors and copy number alterations (CNAs). We also compared prediction accuracy of the sub-regional radiomics model with the whole-tumour radiomics model and conventional clinical factors.

2. Methods

2.1. Study design

Fig. 1 depicts the schema of the present study, with the following steps: Image Acquisition, Volume of Interest Delineation, Sub-region Clustering, Features Extraction, Feature Selection, Model Construction and Validation. CT image datasets from two institutions were used for training an overall survival prediction model and validation, respectively. More specifically, tumour volumes were delineated on the CT scans of the selected OSCC patients, followed by sub-region clustering and radiomics feature extraction of different sub-regions. Features that showed significant correlation with survival were identified and paired with the corresponding clinical survival outcomes for training and validation using a machine learning method. A survival prediction model was constructed based on the training dataset. The model was then tested using the validation dataset by investigating the underlying genomics correlation of the developed survival prediction model with CNAs and clinical factors. We further validated the developed model by comparison with whole-tumour based radiomics model and conventional clinical factors.

2.2. Patients

Two cohorts of OSCC patients from Hangzhou Cancer Hospital and the First Affiliated Hospital of Wenzhou Medical University were retrospectively identified and their CT scans were obtained upon Intuitionat Review Board approval from both hospitals. The written informed consent was waived by IRB based on the retrospective nature of this study. This study was constructed following ethical guidelines of World Medical Association (WMA) Declaration of Helsinki. Inclusion criteria are I) histological diagnosis of OSCC and staged according to the 2002 (version 6.0) American Joint Committee on Cancer staging system; II) medically inoperable or refuse to surgery after discussion by the multidisciplinary treatment team; III) Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤2; and IV) no evidence of severe organ dysfunction. The exclusion criteria are I) early-stage OSCC; II) evidence of distant metastasis at diagnosis; III) prior administration of surgery or chest radiation or chemotherapy; IV) non-treatment related death; and V) incomplete data on CT images and overall survivals.

All patients received a planning CT scan for treatment planning purpose, followed by radiotherapy treatment with a total dose of 54–60 Gy given in 27–30 fractions (2.0 Gy per fraction, 5 days per week). Treatment plans involved 3-dimension conformal photon fields or Intensity modulated photon fields. The majority of OSCC patients received...
definitive concurrent chemoradiotherapy based on cisplatin regimen. For patients with advanced ages or poor performance status, radiotherapy alone was delivered to these patients.

Paired CT images and overall survival outcomes of a total of 87 patients diagnosed between May 2012 and November 2016 from Hangzhou Cancer Hospital were used as the training cohort. Same dataset pairs from 46 patients diagnosed between January 2008 and July 2011 from the First Affiliated Hospital of Wenzhou Medical University were used to validate the developed model and to further improve the model by feeding in genomics information with CNAs. Apart from age and sex, patients' clinical characteristics including clinical stage, ECOG PS, and tumour length were collected for both cohorts.

2.3. Image acquisition

The CT images of the training cohort were obtained from the Brilliance Big Bore CT scanner (Philips Electronics, Eindhoven, Netherlands) in Hangzhou Cancer Hospital. The scanning voltage and tube currents were 120 kVp and 406 mAs. The slice thickness ranged from 3 to 5 mm. The CT images in the validation cohort were scanned from the LightSpeed Pro 16 CT (GE Medical Systems, Milwaukee) in the First Affiliated Hospital of Wenzhou Medical College, with 120 kVp and 150 mAs. The slice thickness was 3–8 mm.

2.4. Volume of interest (VOI) delineation and sub-region clustering

The contoured gross tumour volume (GTV) in the radiation treatment was used as the volume of interest (VOI) in the training cohort. Because the patients' radiation therapy plans in the validation cohort were not well preserved, the VOIs in the validation cohort were depicted by two radiologists all with more than 10 years of experience. The VOI segmentation was performed using open-source software, ITK-SNAP (http://www.itksnap.org/pmwiki/pmwiki.php). The regions of VOIs in the validation cohort were agreed by both the two radiologists. Air region in the VOI was excluded with a Hounsfield Unit (HU) threshold of zero. VOIs were divided into sub-regions based on

**Fig. 1.** Workflow in this study.
the cluster of HU values and local entropy values of CT images. A moving window with the size of 9 × 9 was used in the calculation of local entropy [13] on each slice of CT images. The K-means method was used for clustering sub-regions in this study. The Calinski–Harabasz (CH) value was used as the criterion in selecting the best number of clusters at the patient population level [15]. The number of clusters from 2 to 10 were tested in this study.

2.5. Feature extraction

To compensate for the difference in radiomics features caused by different reconstruction slice thicknesses and pixel sizes [16], the voxel sizes of all CT images in this study were re-constructed to 1 × 1 × 5 mm³. The VOIs were normalized to 64 grey levels to compensate for the variation of CT scanners. For each sub-region, region volume, shape, intensity, and texture were quantified as 548 radiomics features using texture analysis and wavelet decomposition method as described in the study of Vallières et al. [17]. For comparison purpose, 548 radiomics features were also extracted from the whole tumour region for each patient. The radiomics features used in this study were described in Supplementary I. All sub-regional partitioning and radiomics feature extraction were performed on MATLAB 2015b (The Mathworks, Natick, MA).

2.6. Feature selection and survival prediction model construction

To eliminate the potential volume change effect caused by sub-regional analysis on radiomics features, the correlation between the tumour volume and radiomics feature value was assessed using the Pearson correlation method, as compared to the whole tumour region. Radiomics features with a correlation coefficient (CC) of -0.75 were excluded from further study [18]. The redundant features with high internal association (CC > 0.75) of all sub-regional radiomics features were further excluded. The least absolute shrinkage and selection operator (LASSO) for cox algorithm was used to screen features that were highly correlated with survival outcomes [19]. The LASSO algorithm controls the number of selected variables by adjusting the parameter, λ. The objective function of LASSO algorithm is shown in Function 1, where $y$ is truth label, $X$ is the feature matrix, $i$ is the coefficients of features and $\lambda$ is the tuning parameter. The LASSO method was designed to minimize the objective function. The larger the $\lambda$ is, the smaller the coefficients of features are. Features with coefficient of larger than zero were selected. To determine the best $\lambda$ in the LASSO algorithm, the 8-fold cross-validation strategy was used [20]. The resulting the least mean difference between the predicted and actual survival in the cross-validations was used to select the final features. A radiomics score was calculated based on the selected sub-regional radiomics features and corresponding coefficients. The survival prediction model was built based on the radiomics score using the Cox proportional hazards model and a radiomics nomogram was constructed based on this model for visualization purpose.

$$\frac{1}{2}||y - X\hat{\beta}||^2_2 + \lambda||\hat{\beta}||_1$$

(1)

2.7. Prognostic performance evaluation

The predictive performance of the radiomics score was evaluated in the training cohort and verified in the validation cohort using the concordance index (C-index) [21]. The patients were divided into a high-risk group or low-risk group based on the predicted risk using the proposed model. The receiver operating characteristics (ROC) curve was used to determine the best cut-off risk to stratify patients. The ROC curves for 1-year survival, 2-year survival, and 3-year survival were plotted for the two datasets. The Youden index was used to select the best cut-off value where the sum of sensitivity and specificity is maximized [22]. The optimal cut-off in the training dataset was used to stratify patients in the validation dataset. The Kaplan–Meier survival analysis and Log-rank test were used to compare the differences between the survival curves of the two groups [23].

2.8. Association of sub-regional radiomics features with clinical factors and copy number alteration

The Spearman rank correlation test was used to assess the correlation of sub-regional radiomics features included in the survival model with clinical factors and CNAs in the validation cohort. A corresponding $p$-value was used to determine the significance of the correlation ($p$-value < .05). The CNAs of patients in the validation cohort were acquired by whole exon sequencing using the Integrated DNA Technologies (IDT) xGen Exome Research Panel kit for exon capture and sequencing by the Illumina HiSeq 2500. The alignment was performed by bwa 0.7.13 [24]. All CNAs were called by cn.mops [25] package in R language. A total of 1046 CNAs indexes were analysed. The specific CNAs locations of each CNA index were summarized in the supplementary (Supplementary Table S3).
548 whole-tumour radiomics features and 2192 sub-regional radiomics features were extracted from each patient.

3.3. Feature selection result

None of radiomics feature were found to have high correlation (CC > 0.75) with the tumour volume. Three hundred and forty features remained after the internal correlation exclusion. The best lambda was set as 0.157851, with log(lambda) = −1.846106, as shown in Fig. 3a. The feature selection process in the LASSO method was shown in Fig. 3b and c. Seven sub-regional radiomics features with non-zero coefficient at the best lambda were selected in the LASSO method. The detailed information of the seven sub-regional features was described in Supplementary Table S1.

### Table 1

| Characteristic      | Training Cohort (n = 87) | Validation Cohort (n = 46) | p-value |
|---------------------|-------------------------|---------------------------|---------|
| Age, years          | Median (range)          | Median (range)            | .611    |
| Male                | 59                      | 37                        | .122    |
| Female              | 28                      | 9                         | .73     |
| ECOG PS             | 0–1                     | 2                         | .613    |
| T stage             | T3                      | T4                        | .209    |
| N stage             | N0                      | N1                        | .826    |
| Differentiation     | Well                    | Fairly                    | .068    |
| Clinical Stage      | III                     | IVa                       | .914    |
| Treatment modality  | RT alone                | Chemoradiotherapy         | .982    |
| Tumour Length (cm)  | ≤5                      | >5                        |         |

RT: radiation therapy.

### 3.4. Sub-regional radiomics survival prediction model

With the coefficient of each radiomics feature in the LASSO method, the radiomics score can be formulated as:

\[
\text{Radiomics Score for SRPM} = 5.473 
\times \text{Subregion1}_\text{LLL}_\text{GLCM}_\text{inf2h} - 14.175 
\times \text{Subregion1}_\text{HHL}_\text{Histogram}_\text{Uniformity} - 14.671 
\times \text{Subregion1}_\text{HHH}_\text{GLSZM}_\text{SZE} - 9.539 
\times \text{Subregion1}_\text{HHH}_\text{GLSZM}_\text{SZE} + 16.778 
\times \text{Subregion3}_\text{LLL}_\text{GLCM}_\text{inf1h} + 16.158 
\times \text{Subregion3}_\text{HHH}_\text{GLCM}_\text{corm} - 0.116 
\times \text{Subregion4}_\text{GLCM}_\text{Contrast} + 22.5
\]  

A constant value 22.5 was added to the formula to make positive radiomics score values. The radiomics survival prediction model was constructed based on the radiomics score. The constructed nomogram was shown in Fig. 5.

The predictive performance of the model was tested in the training set and validation set. The C-index was 0.729 (0.656–0.801, 95% CI) and 0.705 (0.628–0.782, 95% CI) in the two cohorts, respectively. Our evaluation result reflected good prognostic value of the developed model. High C-index value in the validation cohort showed survival prediction feasibility of the model for test cohorts.

As shown in Fig. 4, the 1-year survival ROC curve showed an AUC of 0.800 (0.704–0.896, 95% CI) in the training cohort and 0.794 (0.652–0.936, 95% CI) in the validation cohort. The stratified high-risk and low-risk group showed significant difference of survival in both the training (p-value < .001, Log-rank test) and validation (p-value < .001, Log-rank test), as shown in Supplementary Fig. S5. The 2-year survival ROC curve showed an AUC of 0.821 (0.711–0.931, 95% CI) in training and 0.805 (0.638–0.973, 95% CI) in validation. The stratified high-risk and low-risk group showed significant difference of survival in both training (p-value < .001, Log-rank test) and validation (p-value = .012, Log-rank test). The 3-year survival ROC curve showed an AUC of 0.811 (0.670–0.952, 95% CI) in training and 0.805 (0.638–0.973, 95% CI) in validation. The stratified high-risk and low-risk group showed significant difference of survival in both the training cohort (p-value < .001, Log-rank test) and validation (p-value < .001, Log-rank test). Results showed clinical utility of the developed model in stratifying high-risk patients regarding 1-year survival, 2-year survival and 3-year survival for treatment strategies adjustment.

### 3.5. Clinical and biological association

The correlation analysis showed that subregion1_HHL_Uniformity was significantly correlated with tumour length (Fig. S6). Subregion1_HHL_SZE and subregion3_HHH_corm were significantly
correlated with ECOG PS. Subregion3.LLL_inf1h was correlated with both clinical stage and tumour length. Subregion4.Contrast was correlated with the tumour length and ECOG PS.

One hundred and ninety-five CNAs showed non-zero variance among patients. Thirty-one CNAs showed significant correlation with at least one of the selected radiomics features (Fig. S7). The correlation analysis showed the underlying relationship between clinical factors, gene expression and radiography characteristics in oesophageal tumours.

3.6. Comparison with whole-tumour based radiomics model

The WRPM were established by the following radiomics score:

\[
\text{Radiomics Score for WRPM} = -11.680 \\
\quad \times \text{WholeRegion}1\text{L}_1\text{LL}_{-}\text{GLCM}\text{inf1h} \\
\quad + 0.386 \\
\quad \times \text{WholeRegion}1\text{L}_1\text{LH}_{-}\text{Histogram}\text{Skewness} - 3.223 \\
\quad \times \text{WholeRegion}1\text{L}_1\text{LH}_{-}\text{Histogram}\text{Uniformity} - 0.021 \\
\quad \times \text{WholeRegion}1\text{L}_1\text{LH}_{-}\text{NGTDM}\text{Strength} - 3.984 \\
\quad \times \text{WholeRegion}1\text{HL}_{1}\text{GLRM}\text{GLV} + 0.002 \\
\quad \times \text{WholeRegion}1\text{HHH}_{1}\text{GLSZM}\text{GLV}
\]

(3)

The WRPM showed a C-index of 0.704 (0.637–0.770, 95%CI) in the training cohort and 0.601 (0.531–0.672, 95%CI) in the validation cohort. The C-index of WRPM was lower than that of SRPM, while the statistical analysis showed non-significant difference between the C-indexes of WRPM and SRPM (p-value = .754[Training]; p-value = .982[Validation], t-test).

3.7. Comparison with clinical model

The clinical stage showed a C-index of 0.510 (0.364–0.656, 95%CI) in the training cohort and 0.515 (0.272–0.756, 95%CI) in the validation cohort. The ECOG PS showed a C-index of 0.528 (0.401–0.655, 95%CI) in the training cohort and 0.578 (0.417–0.740, 95%CI) in the validation cohort. Both clinical stage and ECOG PS showed significantly lower C-index than SRPM in the training cohort (p-value = .006 [clinical stage]; p-value = .004 [ECOG PS], t-test). In the validation cohort, no significant difference was observed at 95% confidence interval for clinical stage (p-value = .059, t-test) and ECOG PS (p-value = .061, t-test). When the confidence interval is at 90%, the difference has statistically significance.

4. Discussion

In this study, we performed a sub-region cluster within the tumour region on planning CT. A survival prediction model for OSCC was then constructed based on the sub-regional radiomics features. The constructed sub-regional radiomics survival prediction model showed high prognostic value in both the training cohort (C-index = 0.729 (0.656–0.801, 95% CI)) and validation cohort (C-index = 0.705 (0.628–0.782, 95%CI)). Consistent results on the validation cohort showed utility of this model in independent datasets. The developed model can provide powerful prognostic information to clinicians before radiation therapy and help tailor treatment strategy for patients. For patients with high risk as evaluated by our prediction model the outcome is dismal with chemoradiotherapy and chemoradiotherapy in combination with target drug or immunotherapy are suggested as shown in many clinical trials [26–28].

We also assessed the correlation between sub-regional radiomics features and CNAs or clinical factors. The sub-regional radiomics features showed potential in reflecting gene expression. The SRPM outperformed the WRPM regarding C-index in both datasets, while not statistically significant. The SRPM showed superior prognostic value than conventional clinical factors, clinical stage and ECOG PS and the difference was statistically significant at 90% confidence level. The encouraging prognostic value of CT-based radiomics may shed light on the pre-radiotherapy tumour evaluation and prognosis of OSCC.

The sub-region cluster performed in this study demonstrated the importance of the sub-region analysis in reflecting tumour heterogeneity of OSCC. This result is consistent with previous studies which suggested the prognostic role of sub-regional heterogeneity [12]. The correlation with clinical factors and gene expression showed the potential of sub-regional radiomics features in reflecting tumour biological behaviour. Segal et.al found that genomic activity of human liver cancers can be decoded by non-invasive imaging, namely radiomics features [29]. Combinations of 28 imaging traits can reconstruct 78% of the global gene expression profiles, revealing cell proliferation, liver synthetic function, and patient prognosis. This study showed the potential of radiomics features to reflect gene expression. Also, Hugo et.al suggested that radiomic signature, capturing intratumor heterogeneity, is associated with underlying gene-expression patterns in lung cancer [30]. In the study of Xia et.al, eight sub-regional CT radiomics features were significantly correlated with prognostic gene modules in hepatocellular carcinoma [14]. In the present study, we found that, in oesophageal cancers, 31CNAs showed significant correlation with at least one of the selected radiomics features, which is consistent with previous studies. It may be of interest for future studies to combine radiomics with genomics in the clinical practice and demonstrate the underlying biological pathway for radiomics [31]. The sub-regional radiomics analysis method may better quantify the tumour sub-region which was
more correlated with the tumour growth or aggressiveness [12]. A seven-feature based radiomics score was constructed in this study including six wavelet-based radiomics features showing the importance of wavelet decomposition in the radiomics analysis. The wavelet features characterized the heterogeneity at multiple spatial scales which may help quantify the significant radiomics features which were prognostic in OSCC [19,32].

For OSCC patients enrolled in the present study, endoscopic ultrasound (EUS) and CT were both used to for staging. EUS combined with CT has proven to provide excellent sensitivity and specificity in the T stage of oesophageal cancer in a series of studies [33,34]. Currently, the CT-based sub-region radiomics model in this study could apply for OS prediction in these patients and suggestion for subsequent treatment choices.

Fig. 4. ROC curves for 1-year (a), 2-year (b) and 3-year (c) survival prediction using developed radiomics survival prediction model in the training cohort (a1, b1, c1) and validation cohort (a2, b2, c2).

Fig. 5. The constructed radiomics nomogram in this study.
Additionally, we did whole-exome sequencing for part of the biopsy specimens during our preliminary experiment and the results indicated that CNAs were the only significant predictor for OS in the studied cohort. In literature, Wang et al. demonstrated that other potential biomarkers identified by whole-exome and whole-genome sequencing are also significantly correlated with EC prognosis [35]. For OSCC patients with high risks identified in the current study, definitive concurrent chemoradiotherapy combined with targeted therapy might be a useful treatment option for these patients. Based on our previous phase III study, patients in the definitive concurrent chemoradiotherapy and Erlotinib (EGFR-TKI) group had a median OS time of 24.9 months compared to 20.9 months in non-erlotinib group (p-value = .05) [36]. There are also some limitations in this study. This is a retrospective study, and the validation cohort is of small size. We did not include other imaging types that normally would be used in clinical practice, i.e. PET. Due to the lack of more biological information of patients, we did not further assess the correlation of developed radiomics model with other biological mechanisms for OSCC. In addition, we did not include superficial oesophageal cancer in our study as it is usually treated by endoscopic submucosal dissection in routine practice. Our future research is to explore the radio-genomics model and prospectively validate the proposed model. In addition, we will further assess the tumour change during radiation therapy regarding our developed radiomics score, thus verify the established model.

5. Conclusion

We developed and validated a sub-regional radiomics survival prediction model for OSCC patients. The established model showed high accuracy in improving personalized treatment for OSCC patients. The sub-regional radiomics analysis showed encouraging potential in predicting survival of OSCC treated by radiotherapy and needed to be further confirmed in larger cohorts.

Grants and acknowledgements

The authors would like to thank Dr. Yi Rong for helpful revision of this manuscript. This work was supported by the Zhejiang Provincial Foundation for Natural Sciences (LZ15H220001: S. Wu), National Natural Science Foundation of China (81672994: S. Wu), Zhejiang Provincial Natural Science Foundation of China (LR16F010001: T. Niu), Zhejiang University Education Foundation ZJU-Stanford Collaboration Fund (T. Niu), National Key Research Plan by the Ministry of Science and Technology of China (2016YFC0104507: T. Niu), Natural Science Foundation of China (81871351: T. Niu), Hangzhou Agriculture and Social Developmental Research Program (20172016A04: S. Wu). The founders had no role in study design, data collection, data analysis, interpretation, writing of the manuscript.

Conflicts of interest

The authors declare no competing financial interests.

Author contributions

Conception and design: T. Niu, S. Wu.
Development of methodology: P. Yang, L. Xu, T. Niu.
Analysis and interpretation of data: P. Yang, X. Wang, L. Yang.
Writing, review, and/or revision of the manuscript: C. Xie, P. Yang, Y. Kuang, T. Niu, S. Wu.

Administrative, technical, or material support: C. Xie, P. Yang, X. Zhang, L. Xu, X. Wang, X. Li, L. Zhang, R. Xie, L. Yang, Z. Jing, H. Zhang, L. Ding, Y. Kuang, T. Niu, S. Wu.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.05.023.

References

[1] Chen M, Huang J, Zhu Z, Zhang J, Li K. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 2013;13:539.
[2] Li Y, Lin Q, Luo Z, Zhao L, Zhu L, Sun L et al. Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy. Int J Clin Exp Med 2015;8(7):10947–55.
[3] Atsumi K, Nakamura K, Abe K, Hirakawa M, Shiroyama Y, Sasaki T et al. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer. J Radiat Res 2013;54(5):890–8.
[4] Lindner K, Palms D, Sensninger N, Hummel R. PET/CT predicts survival in patients undergoing primary surgery for esophageal cancer. Langenbecks Arch Surg 2015; 400(2):229–35.
[5] Myllyeänselä M, Neoral C, Vbta R, Vornackova K, Cinčibucj J, Formanek R et al. The value of 18F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological outcome and survival after preoperative chemoradiotherapy. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc. Czechoslovakia 2012;156(2):171–9.
[6] Yip C, Landau D, Kozarski R, Ganeshan B, Thomas R, Michaelidou A et al. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiology 2014;270(1):141–8.
[7] Reukling A, Hulshoff PJ, van Dijk LV, Muijs CT, Burgerhof JGM, Kats-Ugurlu G et al. Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pretreatment (18)F-FDG PET/CT imaging. J Nucl Med 2017;58(5):723–9.
[8] Hou Z, Zhen W, Li S, Liu J, Sun Y, Yan J et al. Radiomic analysis in contrast-enhanced CT: predict treatment response to chemoradiotherapy in esophageal carcinoma. Oncotarget 2017;8(61):104444–54.
[9] Ganeshan B, Ahaleb S, Young RCD, Chatwin CR, Miles KA. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging 2010;10 Suppl 1:137–43.
[10] Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol 2012;67(2):157–64.
[11] Gatesby RA, Grove O, Gillies RJ. Quantitative imaging in cancer evolution and ecology. Radiology 2013;269(1):8–15.
[12] Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S et al. Intratumoral spatial heterogeneity at perfusion MR imaging predicts recurrence-free survival in locally advanced breast cancer treated with neoadjuvant chemotherapy. Radiology 2018;288(1):26–35.
[13] Wu J, Gentheimer MF, Dong X, Rubin DL, Napel S, Diehn M et al. Robust Intratumor partitioning to identify high-risk subregions in lung cancer: a pilot study. Int J Radiat Oncol Biol Phys 2016;95(5):1504–12.
[14] Xu W, Chen Y, Zhang R, Yan Z, Zhou X, Zhang B et al. Radiogenomics of hepatocellular carcinoma: multiregion analysis-based identification of prognostic imaging biomarkers by integrating gene data-a preliminary study. Phys Med Biol 2018;63 (3):035044.
[15] Liu Y, Liu J, Xiong H, Cao X, Wu J, Wu S. Understanding and enhancement of internal clustering validation measures. IEEE Trans Cybern 2013;43(3):982–94.
[16] Larue R, van Timmeren JE, de Jong EEC, Feliciani G, Leijenaar RTH, Schreurs WMJ et al. Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. Acta Oncol 2017;56(11):1544–53.
[17] Vallieres M, Freeman CR, Skamene SR, El Naqa I, a radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol 2015;60(14):5471–96.
[18] Parada SA, Eichinger JK, Dumont GD, Parada CA, Greenhouse AR, Provencher MT et al. Accuracy and reliability of a simple calibration for measuring glenoid bone loss on 3-dimensional computed tomography scans. Arthroscopy 2018;34(1):84–92.
[19] Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z et al. Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. Radiology 2016;281(3):947–57.
[20] Liang W, Xu L, Yang P, Zhang L, Wan D, Huang Q et al. Novel nomogram for preoperative prediction of early recurrence in intrathoracic cholangiocarcinoma. Front Oncol 2018;8:390.
[21] Park H, Lim Y, Ko ES, Cho H-H, Lee JH, Han BK et al. Radiomics signature on magnetic resonance imaging: association with disease-free survival in patients with invasive breast cancer. Clin Cancer Res 2018;24(19):4705–14.
[22] Hu T, Wang S, Huang L, Wang J, Shi D, Li Y et al. A clinical-radiomics nomogram for the preoperative prediction of lung metastasis in colorectal cancer patients with indeterminate pulmonary nodules. Eur Radiol 2019;29(1):439–49.
[23] Wu Y, Xu L, Yang P, Lin N, Huang X, Pan W et al. Survival prediction in high-grade osteosarcoma using radiomics of diagnostic computed tomography. EBiomedicine 2018;34:27–34.
[24] Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 2009;25(14):1754–60.
[25] Klambauer G, Schwarzauer K, Mayr A, Clevert DA, Mittrecker A, Bodenhofer U, et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res 2012;40(9):e69.
[26] Wald O, Smaglo B, Mok H, Groth SS. Future directions in esophageal cancer therapy. Ann Cardiothorac Surg 2017;6(2):159–66.
[27] Abdo J, Agrawal DK, Mittal SK. Targeted chemotherapy for esophageal cancer. Front Oncol 2017;7:63.
[28] Bolm L, Kasmann L, Paysen A, Karapetis C, Rades D, Wellner UF, et al. Multimodal anti-tumor approaches combined with immunotherapy to overcome tumor resistance in esophageal and gastric cancer. Anticancer Res 2018;38(6):3231–42.
[29] Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007;25(6):675–80.
[30] Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
[31] Grossmann P, Stringfield G, El-Hachem N, Bui MM, Rios Velazquez E, Parmar C, et al. Defining the biological basis of radiomic phenotypes in lung cancer. eLife 2017;6.
[32] Wilson R, Devaraj A. Radiomics of pulmonary nodules and lung cancer. Transl Lung Cancer Res 2017;6(1):86–91.
[33] Puli SR, Reddy JR, Bechtold ML, Antillon D, Ibdah JA, Antillon MR. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008;14(10):1479–90.
[34] Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc 2012;75(2):242–53.
[35] Wang X, Li X, Cheng Y, Sun X, Sun X, Self S, et al. Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma. Hum Genomics 2015;9:22.
[36] Wu SX, Wang LH, Luo HL, Xie CY, Zhang XB, Hu W, et al. Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer. Eur J Cancer 2018;93:99–107.